


What is claimed is:

1. Salts of guanidine derivatives corresponding to the formula



5

wherein

X represents a valence bond, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-NH-NH- or -CH=N-NH-,

R represents a linear or branched C<sub>1</sub>-C<sub>30</sub> alkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl residue, which can be substituted by one or more hydroxyl groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups,

Z represents O-CO-Y, O-S(O)<sub>2</sub>-Y, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C<sub>1</sub>-C<sub>4</sub> alkoxy groups, C<sub>1</sub>-C<sub>4</sub> alkyl groups and/or one or more halogen atoms or one or more amino groups.

2. Salt according to Claim 1, wherein Z represents O-CO-Y.

3. Salt according to Claim 2, wherein R represents a pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, cyclododecyl, tricyclo[5,2,1,0<sup>2,6</sup>]-decyl, bicyclo[2,2,1]-cyclohexyl or toluyl residue.

25

4. Salt according to Claim 2, wherein R represents a decyl residue.

5. Salt according to Claim 2, wherein Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl or 2-hydroxy-2,3-dicarboxylic acid propyl.
- 5
6. Salt according to Claim 2, wherein X represents  $-\text{CH}_2\text{-NH-NH-}$  or  $-\text{CH=N-NH-}$ .
7. Salt according to Claim 2, wherein R represents a decyl residue; X represents  $-\text{CH}_2\text{-NH-NH-}$  or  $-\text{CH=N-NH-}$ ; and Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl, or 2-hydroxy-2,3-dicarboxylic acid propyl.
- 10
8. Salt according to Claim 2, said salt being undecylideneaminoguanidine acetate or undecylideneaminoguanidine lactate.
- 15
9. Salt according to Claim 2, said salt being undecylideneaminoguanidine oenanthate or undecylideneaminoguanidine pelargonate.
10. Salt according to Claim 2, said salt being undecylideneaminoguanidine decanoate.
- 20
11. Salt according to Claim 2, said salt being undecylideneaminoguanidine hexanoate.
12. Salt according to Claim 1, wherein Z is  $\text{O-S(O)}_2\text{-Y}$  (sulfonic acid group), or  $\text{O-P(O)(OH)-Y}$  (phosphoric acid group).
- 25

13. Pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections or viral diseases, comprising one or more salts according to Claim 2.
- 5 14. Pharmaceutical preparation according to Claim 13, further comprising common additives and/or excipients.
- 10 15. Method for the preparation of a pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections or viral diseases, comprising processing a salt according to Claim 2 with common additives and/or excipients to an administrable form.
- 15 16. Method according to Claim 15, wherein the salt is processed to an administrable form by providing approximately equimolar amounts of the corresponding base and acid and processing with common additives and/or excipients.
- 20 17. Use of a pharmaceutical preparation according to Claim 13, for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections or viral diseases.
- 25 18. Method for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections or viral diseases comprising administering to a patient a pharmaceutically effective amount of the salt of Claim 2.